Editas Medicine, Inc. (EDIT)
Largest Insider Buys in Sector
EDIT Stock Price History Chart
EDIT Stock Performance
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis …
Insider Activity of Editas Medicine, Inc.
Over the last 12 months, insiders at Editas Medicine, Inc. have bought $253,868 and sold $1.23M worth of Editas Medicine, Inc. stock.
On average, over the past 5 years, insiders at Editas Medicine, Inc. have bought $837,319 and sold $1.27M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hopfield Jessica (director) — $1.02M.
The last purchase of 45,000 shares for transaction amount of $253,868 was made by Hopfield Jessica (director) on 2024‑05‑13.
List of Insider Buy and Sell Transactions, Editas Medicine, Inc.
| 2024-12-03 | Sale | CEO | 1,618 0.0021% | $2.08 | $3,361 | -3.54% | ||
| 2024-12-03 | Sale | EVP, CHIEF MEDICAL OFFICER | 541 0.0007% | $2.08 | $1,124 | -3.54% | ||
| 2024-09-04 | Sale | CEO | 1,555 0.0018% | $3.42 | $5,325 | -10.86% | ||
| 2024-09-04 | Sale | EVP, CHIEF MEDICAL OFFICER | 518 0.0006% | $3.42 | $1,774 | -10.86% | ||
| 2024-07-25 | Sale | EVP, CHIEF SCIENTIFIC OFFICER | 11,886 0.0141% | $5.42 | $64,370 | -40.57% | ||
| 2024-07-19 | Sale | EVP, CHIEF MEDICAL OFFICER | 6,619 0.0084% | $5.21 | $34,456 | -32.80% | ||
| 2024-06-04 | Sale | CEO | 12,191 0.0142% | $5.50 | $66,997 | -38.26% | ||
| 2024-06-04 | Sale | EVP, CHIEF MEDICAL OFFICER | 511 0.0006% | $5.50 | $2,808 | -38.26% | ||
| 2024-05-20 | Sale | EVP, CHIEF FINANCIAL OFFICER | 22,337 0.0276% | $5.61 | $125,404 | -32.16% | ||
| 2024-05-13 | director | 45,000 0.0541% | $5.64 | $253,868 | -33.98% | |||
| 2024-03-05 | Sale | CEO | 77,824 0.0981% | $9.42 | $732,884 | -44.80% | ||
| 2024-03-04 | Sale | SVP, CHIEF MEDICAL OFFICER | 20,327 0.0237% | $9.42 | $191,425 | -49.14% | ||
| 2023-12-05 | Sale | EVP, CBO AND CTO | 103 0.0001% | $10.90 | $1,122 | -49.09% | ||
| 2023-11-14 | Sale | EVP, CBO AND CTO | 695 0.0008% | $8.21 | $5,706 | -32.59% | ||
| 2023-11-07 | Sale | EVP, CBO AND CTO | 139 0.0002% | $8.40 | $1,168 | -33.46% | ||
| 2023-09-06 | Sale | EVP, CBO AND CTO | 103 0.0001% | $8.82 | $908 | -21.66% | ||
| 2023-08-11 | Sale | EVP, CBO AND CTO | 702 0.0009% | $8.59 | $6,033 | -14.46% | ||
| 2023-08-08 | Sale | EVP, CBO AND CTO | 141 0.0002% | $8.39 | $1,183 | -16.18% | ||
| 2023-07-19 | Sale | SVP, CHIEF MEDICAL OFFICER | 4,317 0.0062% | $8.80 | $37,990 | -10.49% | ||
| 2023-06-05 | Sale | CEO | 6,486 0.0095% | $9.50 | $61,638 | -12.82% |
Insider Historical Profitability
| Hopfield Jessica | director | 67700 0.082% | $1.31 | 4 | 0 | <0.0001% |
| VIKING GLOBAL INVESTORS LP | 2729808 3.3069% | $1.31 | 1 | 0 | ||
| VIKING GLOBAL PERFORMANCE LLC | 2729808 3.3069% | $1.31 | 1 | 0 | ||
| Flynn James E | 10 percent owner | 954700 1.1565% | $1.31 | 1 | 0 | +20.25% |
| MULLEN JAMES C | CEO | 75898 0.0919% | $1.31 | 2 | 2 | <0.0001% |
Institutional Investor Ownership
| State Street | $65M | 10.65 | 8.76M | +72.8% | +$27.38M | <0.01 | |
| The Vanguard Group | $63.48M | 10.4 | 8.56M | +1.11% | +$695,550.80 | <0.01 | |
| BlackRock | $58.12M | 9.53 | 7.83M | -0.08% | -$45,914.96 | <0.01 | |
| Deep Track Capital Lp | $41.01M | 6.72 | 5.53M | +0.99% | +$402,193.68 | 0.19 | |
| Dimensional Fund Advisors | $19.35M | 3.17 | 2.61M | +9% | +$1.6M | 0.01 |